MULTIPLE DRUG RESISTANCE PROTEINS OF PULMONARY SOMATIC CELLS AND THEIR SPECIFIC EXPRESSION IN FIBROUS CAVERNOUS TUBERCULOSIS

Cells of the host containing special proteins-transporters, so-called proteins of multiple drug resistance (MDR proteins) can contribute to the drug resistance formation.

Goal of the study: to define specific expression of gene and distribution of main MDR proteins (MDR1/Pgp, MRP1, lRP, BCRP) in the pulmonary cells in case of active tuberculosis.

Materials and methods. Expression of MDR protein genes was evaluated by RT-PCR for mRNA isolated from the surgical specimen of fibrous cavernous tuberculosis patients. Localization of MDR proteins was performed by immunohistochemical staining and confocal laser microscopy.

Main results. Intensity of MDR protein genes expression varies in different zones of tuberculous lesions: MDR1 and BCRP are characterized by the highest level and MRP1 gene is characterized by the minimum level. The level of lRP gene expression depends on the inflammation zone and it is maximum in perifocal zone where protein is detected in the cells of alveolar epithelium and macrophages. High expression of MDR protein genes in various parts of tuberculous lesions witnesses about the potential involvement of these proteins in the development of drug resistance to anti-tuberculosis drugs.

1. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, vol. 92, no. 16, pp. 1295-1302.

2. Borst P., Oude Elferink R. Mammalian ABC transporteres in health and disease. Ann. Rev Biochem., 2002, vol. 71, pp. 537-592.

3. Cegielski J.P., Dalton T., Yagui M. et al. Global Preserving Effective TB Treatment Study (PETTS) Investigators. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis., 2014, vol. 59, no. 8, pp. 1049-1063.

4. Erokhina M., Rybalkina E. Barsegyan G. et al. The toxicity of rifampicin polylactic acid nanoparticles against Mycobacterium Bovis BCG and human macrophage THP-1 cell line, 2015 (98), IOP Conf. Series: Materials Science and Engineering. 98 (2015) 1-8, 012017 doi:10.1088/1757-899X/98/1/012017

5. Fletcher J.I., Williams R.T., Henderson M.J. et al. ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat., 2016, vol. 26, pp. 1-9.

6. Florea B.I., van der Sandt I.C., Schrier S.M. et al. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br. J. Pharmacol., 2001, vol. 134, no. 7, pp. 1555-1563.

7. Fudin J., Fontenelle D.V., Fudin H.R. et al. Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone. J. Pain Palliat. Care Pharmacother., 2013, vol. 27, no. 3, pp. 261-267.

8. Furecz S. Chemical and biological properties of rifampicin. Antibiot Chemother., 1970, vol. 16, pp. 316-351.

9. Garcia-Carrasco М., Mendoza-Pinto C., Macias Diaz S. et al. P-glycoprotein inautoimmune rheumatic diseases. Autoimmunity Reviews, 2015, vol. 14,pp. 594-600.

10. Hamilton K.O., Backstrom G., Yazdanian M.A. et al. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci., 2001, vol. 90, no. 5, pp. 647-658.

11. Hopfner K.P. Invited review: Architectures and mechanisms of ATP binding cassette proteins. Biopolymers, 2016, vol. 105, no. 8, pp. 492-504.

12. Khamisipour G., Jadidi-Niaragh F., Jahromi A.S. et al. Mechanisms of tumor cell resistance to the current targeted-therapy agents. Tumour Biol., 2016, May 7. Epub ahead of print.

13. Maliepaard M., Scheffer G., Faneyte I. et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Tumor biology, 2001, vol. 61, pp. 3458-3464.

14. Maslov D.A., Shur K. V., Bekker O.B. et al. Draft Genome Sequences of Two Pyrazinamide-Resistant Clinical Isolates, Mycobacterium tuberculosis 13-4152 and 13-2459. Genome Announc., 2015, vol. 3, no. 4.

15. Mitnick C.D., Rodriguez C.A., Hatton M.L. et al. RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative). Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One, 2016 May 25;11(5):e0155968.doi:0.1371/journal.pone.0155968.

16. Nusrath Unissa A., Hassan S., Indira Kumari V. et al. Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. J. Mol. Graph Model., 2016, vol. 23, pp. 20-32.

17. Sheps J.A., Ling V. Preface: the concept and consequences of multidrug resistance. Pflugers Arch., 2007, vol. 453, no. 5, pp. 545-553.

18. Scheffer G.L., Wijngaard P.L.J, Flens M.J. et al. The drug resistance-related protein LRP isthe human major vault protein. Nature Med., 1995, vol. 1, pp. 578-582.

19. Scheffer G.L., Pijnenborg A.C.L.M., Smit E.F. et al. Multidrug resistance related molecules in human and murine lung. J.Clin. Pathol., 2002, vol. 55, pp. 332-339.